Clinical Trial Update: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the use of letermovir for prevention of CMV infection in hematopoietic stem cell transplant recipients, evaluated with mNGS outc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cmv Infection
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: CMV Infection, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: UNKNOWN